Gelonghui February 20 丨Huadong Pharmaceutical (000963.SZ) stated on February 15, 2023 at 14:30-16:00; on February 16, 11:00-11:40 and 14:00-15:00 during on-site research by the agency, that the company's Belling series and acarbose series products are expected to grow steadily this year, an improvement over the previous two years. The company's important varieties of diabetes pipelines are also expected to continue to grow at a relatively rapid pace this year. Both indications of liraglutide injections are expected to be approved for marketing this year, bringing new increases. Immunosuppressant products have maintained steady growth, and core products in the cardiovascular field have maintained rapid growth. Carbifene acetate for injection, micafennet sodium for injection, as well as newly approved sorafenib tablets and cagalacin tablets, etc. are also expected to have a positive impact on the company's business performance this year. In addition, the company is responsible for marketing Nihina® (Alogliptin benzoate tablets), epicaritin softgels, etc. are also expected to contribute to some sales performance. The company collaborated with Keji Pharmaceutical to commercialize the zevocene injection in China submitted a marketing license application in October 2022 and is currently in the review stage.